The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients

Tumor Biology ◽  
2015 ◽  
Vol 37 (6) ◽  
pp. 7675-7684 ◽  
Author(s):  
Yan-Yun Zhu ◽  
Wen Si ◽  
Tie-Feng Ji ◽  
Xiao-Qin Guo ◽  
Yi Hu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Hormone Receptors ◽  
Breast Cancer Patients ◽  
Metastatic Lesions ◽  
Her 2

scholarly journals Gambaran Usia dan Stadium Klinis Pasien Kanker Payudara yang dilakukan Pemeriksaan Imunohistokimia di Rumah Sakit Abdul Wahab Sjahranie pada Tahun 2018

2020 ◽  
Vol 8 (2) ◽  
pp. 126-140
Author(s):  
Ade Yusuf Yulianto ◽  
Hadi Irawiraman ◽  
P.M.T. Mangalindung Ompusunggu
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Clinical Stage ◽  
Descriptive Study ◽  
Regional Hospital ◽  
Breast Cancer Patients ◽  
Immunohistochemical Examination ◽  
Ki 67 ◽  
Her 2

ABSTRACKBreast cancer still occupies the highest incidence of all types of malignancies in women. Based on data recorded at Abdul Wahab Sjahrenie Hospital, 200 new cases are found each year. Immunohistochemical profile examination has been used extensively as a basis for classifying breast cancer molecularly. Expression of hormone receptors (ER, PR) and HER-2 found in immunohistochemical examinations are useful for determining therapeutic options that fit the patient's needs. The purpose of this descriptive study was to determine the characteristics of the immunohistochemical profile of breast cancer patients in Abdul Wahab Sjahranie Regional Hospital Samarinda in the January-December 2018 period based on age and clinical stage that had been examined by immunohistochemical examination including the expression of ER PR, Ki-67 and HER2. Method: This study used a cross-sectional descriptive study design by taking secondary data from breast cancer patients who had performed immunohistochemical examinations at Abdul Wahab Sjahranie Regional Hospital Samarinda in the January 2018 - December 2018 period. From 479 breast cancer patients came to Abdul Wahab Regional Hospital Sjahranie Samarinda, only 177 (37.18%) patients did immunohistochemical examinations. Most patients aged 40-49 were 65 patients (36.7%) had breast cancer, the highest clinical stage IIIB with 92 cases (52%), the Ki-67 with severe highest interpretation, range> 30% with 73 patients (41.2%), more positive ER than negative, in 93 patients (52.5%), while negative examination results 84 patients (47.5%). PR is the same as ER, which is 96 patients (54.2%), while negative examination results are 81 patients (45.8%). Most HER-2 results were negative, in 109 patients (61.6%). In this study the highest number of cases of breast cancer patients ranged between the ages of 40-49 years and at least aged 70 years and above. The clinical stage is most often found in stage IIIB (advanced). Ki-67 examination was found most frequently in severe interpretations. Examination of estrogen receptors is found to be most widely in positive interpretation. Positive progesterone tests to be most widely than negative examinations. Her-2 examination was found to be most widely in negative interpretation Keywords: Immunohistochemical examination, Hormone receptors, HER-2, Clinical Stadium

scholarly journals Investigation of the change in the biological structure of the tumor in metastatic breast cancer

2021 ◽  
Vol 8 (3) ◽  
pp. 171-174
Author(s):  
Veysel Haksoyler ◽  
Tolga Koseci ◽  
Timucin Cil ◽  
Berna Bozkurt Duman ◽  
Polat Olgun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Tumor Biology ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Metastatic Site ◽  
Significant Difference ◽  
Her 2

Objective: When metastasis develops in some breast cancer patients, hormone receptors (HR) and Human Epidermal Growth Factor-2 (Her-2) status can change and the tumor alters its character. We tried to determine the rate of these changes in tumor biology in 110 patients that we followed in our clinic and performed the change of the biopsy from the metastatic site (re-bx). We aimed to determine the biological changes of tumors and, contribute to the literature by examining the relationship of these changes with the adjuvant endocrine treatments (ET) or chemotherapy type (CT). Material and Methods: We included 110 metastatic breast cancer patients in our study. These patients had previously completed their local treatments followed by CT, and those with positive HR completed ET. After the first metastasis developed in the patients, we performed metastasectomy or biopsy from the metastatic site. Results: The median ki-67 value was 25% at the time of primary diagnosis and 30% in re-bx. 20.9% of patients estrogen receptor (ER), 31.8%  of patients progesterone receptor (PR) and 26.3% of patients Her-2 changed when metastasis developed. Conclusions: We found that the metastatic tumor has more aggressive properties than the primary tumor. Adjuvant chemotherapy and endocrine treatments or the location of metastasis did not make a significant difference in tumor biology.

Clinical significance of Stratifin, ERα and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients

2010 ◽  
Vol 43 (4-5) ◽  
pp. 380-386 ◽  
Author(s):  
Sameer Mirza ◽  
Gayatri Sharma ◽  
Rajinder Parshad ◽  
Anurag Srivastava ◽  
Siddartha Datta Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Promoter Methylation ◽  
Breast Cancer Patients ◽  
Serum Dna

scholarly journals Clinical Significance of Annexin A2 Expression in Breast Cancer Patients

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 2
Author(s):  
Lee D. Gibbs ◽  
Kelsey Mansheim ◽  
Sayantan Maji ◽  
Rajesh Nandy ◽  
Cheryl M. Lewis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Cell Lines ◽  
Breast Cancer Subtypes ◽  
Enzyme Linked Immunosorbent Assay ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Cancer Subtypes ◽  
Tumor Tissues

Increasing evidence suggests that AnxA2 contributes to invasion and metastasis of breast cancer. However, the clinical significance of AnxA2 expression in breast cancer has not been reported. The expression of AnxA2 in cell lines, tumor tissues, and serum samples of breast cancer patients were analyzed by immunoblotting, immunohistochemistry, and enzyme-linked immunosorbent assay, respectively. We found that AnxA2 was significantly upregulated in tumor tissues and serum samples of breast cancer patients compared with normal controls. The high expression of serum AnxA2 was significantly associated with tumor grades and poor survival of the breast cancer patients. Based on molecular subtypes, AnxA2 expression was significantly elevated in tumor tissues and serum samples of triple-negative breast cancer (TNBC) patients compared with other breast cancer subtypes. Our analyses on breast cancer cell lines demonstrated that secretion of AnxA2 is associated with its tyrosine 23 (Tyr23) phosphorylation in cells. The expression of non-phosphomimetic mutant of AnxA2 in HCC1395 cells inhibits its secretion from cells compared to wild-type AnxA2, which further suggest that Tyr23 phosphorylation is a critical step for AnxA2 secretion from TNBC cells. Our analysis of AnxA2 phosphorylation in clinical samples further confirmed that the phosphorylation of AnxA2 at Tyr23 was high in tumor tissues of TNBC patients compared to matched adjacent non-tumorigenic breast tissues. Furthermore, we observed that the diagnostic value of serum AnxA2 was significantly high in TNBC compared with other breast cancer subtypes. These findings suggest that serum AnxA2 concentration could be a potential diagnostic biomarker for TNBC patients.

Sign in / Sign up

Export Citation Format

Share Document